| 12383526 |
Optimized sigma-1 agonist method of responder selection and treatment |
Mohammad Afshar, Frédéric Parmentier |
2025-08-12 |
| 12285403 |
A2-73 as a therapeutic for insomnia, anxiety and agitation |
— |
2025-04-29 |
| 12280034 |
Sigma-1 receptor agonist systolic blood pressure therapy |
— |
2025-04-22 |
| 12180174 |
A2-73 crystalline polymorph compositions of matter and methods of use thereof |
Alani Selvey |
2024-12-31 |
| 12138240 |
Treatment of cardiac dysfunction |
— |
2024-11-12 |
| 11896590 |
Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof |
— |
2024-02-13 |
| 11839600 |
Neurodevelopmental disorder therapy |
— |
2023-12-12 |
| 11813242 |
A2-73 as a therapeutic for insomnia, anxiety, and agitation |
— |
2023-11-14 |
| 11690821 |
A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy |
Cameron DURRANT |
2023-07-04 |
| 11622955 |
Sigma-1 receptor agonist systolic blood pressure therapy |
— |
2023-04-11 |
| 11498908 |
A2-73 crystalline polymorph compositions of matter and methods of use thereof |
Alani Selvey |
2022-11-15 |
| 11446275 |
Neurodevelopmental disorder therapy |
— |
2022-09-20 |
| 11337953 |
A2-73 as a therapeutic for insomnia, anxiety, and agitation |
— |
2022-05-24 |
| 11071723 |
Treatment of cardiac dysfunction |
— |
2021-07-27 |
| 10933062 |
Analgesic therapeutic and method, 1-(3-4(((1 R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof |
— |
2021-03-02 |
| 10888543 |
Neurodevelopmental disorder therapy |
— |
2021-01-12 |
| 10813907 |
A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy |
Cameron DURRANT |
2020-10-27 |
| 10507196 |
Neurodevelopmental disorder therapy |
— |
2019-12-17 |
| 10195192 |
Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof |
— |
2019-02-05 |